{
    "clinical_study": {
        "@rank": "83991", 
        "arm_group": [
            {
                "arm_group_label": "Placebo (Multiple dose)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "Dose 1, Single dose", 
                "arm_group_type": "Experimental", 
                "description": "Low dose"
            }, 
            {
                "arm_group_label": "Dose 2, Single dose", 
                "arm_group_type": "Experimental", 
                "description": "Medium dose"
            }, 
            {
                "arm_group_label": "Dose 3, Single dose", 
                "arm_group_type": "Experimental", 
                "description": "High dose"
            }, 
            {
                "arm_group_label": "Dose 4, Multiple dose", 
                "arm_group_type": "Experimental", 
                "description": "Low dose"
            }, 
            {
                "arm_group_label": "Dose 5, Multiple dose", 
                "arm_group_type": "Experimental", 
                "description": "Medium dose"
            }, 
            {
                "arm_group_label": "Dose 6, Multiple dose", 
                "arm_group_type": "Experimental", 
                "description": "High dose"
            }, 
            {
                "arm_group_label": "Placebo (Single dose)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Safety, tolerability and pharmacokinetics of  single and multiple oral doses of BI 113608 in\n      healthy Chinese, Japanese and Caucasian male volunteers."
        }, 
        "brief_title": "Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        -Healthy male volunteers according to the following criteria: Based upon a complete\n        medical history, including the physical examination, vital signs (Blood Pressure, Pulse\n        Rate), 12-lead Electrocardiogram, clinical laboratory tests\n\n          -  Chinese ethnicity, Japanese ethnicity according to the following criteria Japanese;\n             born in Japan, be a current Japanese passport holder, have lived outside of Japan <10\n             years, and have parents and grandparents who were all born in Japan Chinese; ethnic\n             Chinese, born in China or ethnic Chinese born outside of China, and a descendent of 4\n             ethnic Chinese grandparents who were all born in China\n\n          -  Caucasian\n\n          -  Age older than 20 and younger than 45 years\n\n          -  Normal lung function testing\n\n          -  Normal peripheral oxygen saturation as determined by non-invasive pulse oxymetry\n\n          -  Body Mass Index more than 18.5 and Body Mass Index less than 25 kg/m2 for Japanese\n             and Chinese\n\n          -  Body Mass Index more than 18.5 and Body Mass Index less than 29.9 kg/m2 for\n             Caucasians\n\n          -  Signed and dated written informed consent prior to admission to the study in\n             accordance with Good Clinical Practice and the local legislation.\n\n        Exclusion criteria:\n\n          -  Any finding of the medical examination (including Blood Pressure, Pulse Rate and\n             Electrocardiogram) deviating from normal and of clinical relevance\n\n          -  Any evidence of a clinically relevant concomitant disease\n\n          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          -  Surgery of the gastrointestinal tract (except appendectomy)\n\n          -  Diseases of the central nervous system (including but not limited to any kind of\n             seizures, migraine, stroke or psychiatric disorders) within the past 6 month\n\n          -  History of relevant orthostatic hypotension, fainting spells or blackouts.\n\n          -  Chronic or relevant acute infections\n\n          -  History of relevant allergy/hypersensitivity (including allergy to drug or its\n             excipients)\n\n          -  Intake of drugs with a long half-life (> 24 hours) within at least one month or less\n             than 10 half-lives of the respective drug prior to administration or during the trial\n\n          -  Use of drugs which might reasonably influence the results of the trial or that\n             prolong the QT/QTc interval based on the knowledge at the time of protocol\n             preparation within 10 days prior to administration or during the trial\n\n          -  Participation in another trial with an investigational drug within two months prior\n             to administration or during the trial\n\n          -  Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)\n\n          -  Inability to refrain from smoking on trial days\n\n          -  Alcohol abuse (more than 20 g/day)\n\n          -  Drug abuse\n\n          -  Blood donation (more than 100 mL within four weeks prior to administration or during\n             the trial)\n\n          -  Excessive physical activities (within one week prior to administration or during the\n             trial)\n\n          -  Any laboratory value outside the reference range that is of clinical relevance\n\n          -  Inability to comply with dietary regimen of trial site\n\n          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a\n             QTc interval >450 ms);\n\n          -  A history of additional risk factors for Torsades de pointes (e.g., heart failure,\n             hypokalemia, family history of Long QT Syndrome)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "98", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922349", 
            "org_study_id": "1314.9"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dose 5, Multiple dose", 
                "description": "Medium dose (Multiple dosing)", 
                "intervention_name": "BI 113608", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (Multiple dose)", 
                "description": "Placebo (Multiple dosing)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose 4, Multiple dose", 
                "description": "Low dose (Multiple dosing)", 
                "intervention_name": "BI 113608", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (Single dose)", 
                "description": "Placebo (Single dosing)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose 3, Single dose", 
                "description": "High dose (Single dosing)", 
                "intervention_name": "BI 113608", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose 2, Single dose", 
                "description": "Medium dose (Single dosing)", 
                "intervention_name": "BI 113608", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose 1, Single dose", 
                "description": "Low dose (Single dosing)", 
                "intervention_name": "BI 113608", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dose 6, Multiple dose", 
                "description": "High dose (Multiple dosing)", 
                "intervention_name": "BI 113608", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "1314.9.8201 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "8", 
        "official_title": "Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 113608 in Healthy Male Asian and Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety (MFDS)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number (%) of subjects with drug-related adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "Number of participants with clinically relevant findings in physical examination", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "Number of participants with clinically relevant findings in vital signs", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "Number of participants with clinically significant abnormalities in electrocardiogramm (ECG) results", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "Number of participants with significant changes from baseline laboratory measurements", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "Diffusing capacity of the lung for carbon monoxide (DLCO)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "Forced expiratory volume in one second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922349"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "tmax (time from dosing to maximum measured concentration in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma from time 0 to time of last quantifiable data point)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "t1/2 (terminal half-life of the analyte in plasma after the first dose)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "t1/2,ss (terminal half-life of the analyte in plasma at steady state)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "RA,Cmax (Accumulation ratio of the analyte in plasma at steady state after multiple oral administration over a uniform dosing interval t, expressed as ratio of Cmax at steady state and after single dose)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }, 
            {
                "measure": "RA,AUC (Accumulation ratio of the analyte in plasma at steady state after multiple dose administration over a uniform dosing interval t, expressed as ratio of AUC at steady state and after single dose)", 
                "safety_issue": "No", 
                "time_frame": "up to 23 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}